Lipid nanoparticle technology

Lipid nanoparticles (LNPs) have been around for many years but garnered lots of attention due to their use within certain COVID-19 mRNA vaccines. In their basic form, LNPs are a protective lipid shell wrapped around cargo intended for cellular uptake and processing. LNPs are a leading cargo and gene delivery vehicle with clinical applications. They possess great potential in transporting diverse therapeutic substances and are championed as a desirable nonviral alternative.

Lipid nanoparticle composition

LNP composition continues to diversify and can be tailored for specific use cases, cell types, environments or cargo types. Solid lipid nanoparticles are nanoscale particles composed of solid lipids. One key benefit is their ability to encapsulate various drugs, including hydrophilic, lipophilic and poorly soluble compounds. The solid lipid matrix provides a stable environment for drug incorporation, protecting it from degradation and improving its bioavailability.

LNPs - A safer, nonviral vector alternative in gene therapy

Challenges with viral vectors in gene transfer

Modified viruses like lentivirus, herpes simplex virus, retrovirus, adeno-associated virus, etc., have been extensively employed as carriers for gene transfer. Viruses facilitate effective gene transfer by leveraging their favorable cellular uptake and intracellular transportation mechanisms.

Nevertheless, viral vectors possess certain inherent limitations, including

• Challenges in manufacturing.
• Restricted chances for repeated administrations due to acute inflammatory reactions and unintended immune responses.
• Additionally, some viral vectors may present risks of insertional mutagenesis, where foreign DNA becomes integrated into the host genome.

Advantages of nonviral vectors in gene delivery

Nonviral vectors have emerged as a safer and more flexible alternative to viral vectors, addressing the challenges associated with viral carriers. Nonviral gene delivery methods utilize synthetic or natural compounds, and physical forces, to transport DNA into cells. These materials are typically less toxic and provoke fewer immune responses compared to viral vectors. Moreover, nonviral approaches can achieve cell or tissue specificity by leveraging specific cell functions in chemical or biological carriers, while physical techniques allow for precise targeting. An additional practical benefit of nonviral methods include the possibility of repeated administration.

Lipid nanoparticles (LNPs) as an optimal nonviral platform

Among different nonviral gene vectors, lipid nanoparticles (LNPs) represent an optimal platform to combine safety and efficacy in a single delivery system. LNPs have demonstrated strong capabilities to compact and deliver various nucleic acid molecules, ranging in size from small RNA molecules to large chromosomes, into cells. LNPs can be easily customized by incorporating targeting ligands on their surface.

Recent advancements in lipid-based gene delivery systems have significantly enhanced the effectiveness and expression levels of targeted genes, overcoming obstacles that previously limited nonviral delivery methods. The improved design of structure and activity has expanded the potential of LNPs in gene therapy for oncology and other diseases.

Nonviral methods are commonly considered less effective than viral methods, and often, the duration of gene expression is relatively short-lived. Nevertheless, recent advancements indicate that certain physical methods for gene delivery have achieved levels of efficiency and expression duration that hold clinical significance.

LNP manufacturing methods for mRNA delivery

Various methods are employed to produce lipid nanoparticles (LNPs) for mRNA delivery.

High-pressure homogenization

High-pressure homogenization involves subjecting a mixture of lipids and an aqueous phase to high pressure, forming LNPs with a narrow size distribution.

Hot homogenization

Hot homogenization utilizes heating and mixing lipids and the aqueous phase, followed by homogenization at an elevated temperature to create LNPs.

Cold homogenization

Cold homogenization involves mixing lipids and the aqueous phase at low temperatures before homogenization to generate small-sized particles.

Other techniques

• Microemulsion method
• Solvent-based emulsification/evaporation,
• Emulsification-solvent evaporation,
• Sonication/ultrasound
• Solvent injection
• Phase reversal
• Membrane contraction

Each technique provides unique approaches for producing LNPs suitable for mRNA delivery.

Applications of LNPs in mRNA vaccines, ASO delivery, and RNAi therapeutics

LNPs in mRNA-based vaccines: A crucial role in COVID-19 vaccination

• LNPs can ensure the effective and safe delivery of mRNA molecules to target cells for therapeutic protein synthesis. They function by protecting mRNA from degradation and facilitating cellular uptake to specific tissues or organs. This technology has played a crucial role in developing mRNA-based vaccines, including the successful COVID-19 vaccines. Moreover, LNPs hold promise in gene therapies, offering a potential cure for genetic disorders by delivering corrective mRNA.

LNPs in mRNA-based vaccines: A crucial role in COVID-19 vaccination

• LNPs have gained significant attention as a favored choice for delivering antisense oligonucleotides (ASOs) due to their unique properties. The precise formulation of LNPs plays a crucial role in determining their behavior in biological systems. By fine-tuning the parameters of the delivery methods, researchers can design LNPs with specific characteristics that enhance ASO delivery, such as improved stability, enhanced release kinetics and targeting capabilities.

Lipid nanoparticles in RNAi therapeutics: Targeted silencing for disease treatment

• RNA interference (RNAi) is a powerful therapeutic approach that targets and silences specific disease-causing genes. To effectively deliver RNAi therapeutics to target cells and tissues, researchers have explored the use of lipid nanoparticles (LNPs) as carriers. These LNPs are composed of biodegradable lipids that can efficiently encapsulate RNAi molecules. This RNAi delivery approach using lipid nanoparticles shows promising potential for treating a wide range of diseases, making it an exciting area of research in the field of medicine and therapeutics.

Lipid nanoparticles in RNAi therapeutics: Targeted silencing for disease treatment

• Vaccine delivery using LNPs has emerged as a promising and innovative approach in vaccinology. These have shown great promise as delivery vehicles for vaccine adjuvants and antigens. The targeted delivery of adjuvants and antigens to immune cells using lipid-based nanoparticles can lead to enhanced immune responses, potentially improving the efficacy of vaccines. mRNA-based vaccines, in particular, have gained attention due to their potential to respond to emerging pathogens rapidly and allow personalized medicine. LNPs have become a leading candidate for mRNA vaccine delivery due to their biocompatibility and ability to protect mRNA from degradation. LNPs offer high encapsulation capacity, controlled and sustained release and enhanced vaccine stability and immunogenicity. Through careful design and formulation strategies, LNP-mRNA interactions can be optimized to promote cellular uptake and intracellular delivery.

Advantages of LNPs

Higher bioavailability and therapeutic efficacy in mRNA delivery

• LNPs provide an effective means to deliver mRNA molecules into target cells, ensuring higher bioavailability and therapeutic efficacy. These also shield mRNA from degradation, preserving its integrity during transportation and uptake and enhancing the stability of the delivered cargo. LNPs can be modified to target specific tissues or organs, enabling precise delivery of mRNA therapeutics to the intended site while minimizing off-target effects. LNPs can encapsulate a wide range of mRNA sequences, allowing for the development of diverse mRNA-based therapies, including vaccines and gene therapies. These have also shown lower immunogenicity compared to viral vectors, reducing the risk of unwanted immune responses in recipients. LNPs offer a promising avenue for treating genetic disorders by delivering corrective mRNA to affected cells, potentially providing a cure for certain conditions.

LNPs in ASO delivery: Biocompatibility and shielding

• There are several key advantages of using LNPs as carriers for ASO delivery. One major advantage is their biocompatibility, meaning that LNPs are well-tolerated by biological systems and do not cause significant adverse reactions. Additionally, LNPs have been engineered to minimize interactions with the immune system, reducing the likelihood of triggering immune responses, which could potentially interfere with the therapeutic effect of ASOs. LNPs also have the ability to shield the delicate ASO molecules from enzymatic degradation and nuclease attack in the extracellular environment. This protection ensures the ASOs remain intact and capable of effectively reaching their target cells without losing their therapeutic potential.

Advantages in RNAi: Protecting and facilitating uptake

• The advantage of using LNPs in delivering RNAi lies in their ability to protect the fragile RNAi cargo and facilitate its uptake by target cells. Moreover, some LNPs are designed to be rapidly eliminated from the body after delivering their cargo, reducing the risk of long-term accumulation and potential toxicity.

LNP-mediated vaccine delivery: Precision and swift response

• One of the key advantages of LNPs for vaccine delivery is the ability to modify their surface with targeting ligands, enabling specific delivery to immune cells or antigen-presenting cells, thereby enhancing the immune response. The use of mRNA-based vaccines in LNPs enables a swift response to emerging pathogens by quickly designing and producing new vaccines based on their genetic sequences. These offer several advantages as delivery vehicles of antigens, including improved stability and controlled release of vaccine components.

Disadvantages of LNPs

Liver tropism

This is a recognized as LNPs have a tendency to accumulate predominantly in the liver after systemic administration, leading to off-target effects and potential adverse reactions. This excessive liver accumulation can hinder the LNPs' ability to reach target tissues or organs, limiting their therapeutic efficacy for diseases located outside the liver. However, to address this limitation, researchers have been actively exploring the use of a selective organ targeting (SORT) strategy. This approach involves designing various lipid classes to enable tissue-specific gene delivery and editing using CRISPR-Cas technology. The manipulation of internal and/or external charges in the formulated LNPs plays a pivotal role in achieving tissue-specific delivery and enhancing the overall performance and safety of LNPs for therapeutic delivery.

Instability

The stability of LNPs can be affected by several factors, including pH, temperature and lyophilization (freeze-drying). Fluctuations in pH can lead to changes in the LNP structure, affecting the encapsulation and release of therapeutic cargo. Similarly, exposure to extreme temperatures may cause LNPs to undergo phase transitions or degrade, leading to a loss of cargo integrity. Lyophilization, a common technique used for long-term storage of LNPs, can also impact their stability. The freeze-drying process can induce stresses on the LNPs, potentially leading to aggregation or altered drug release profiles upon reconstitution. Researchers are investigating various formulation strategies and stabilizing agents to address these challenges and improve the stability of LNPs.

Circulation

One of the disadvantages of lipid nanoparticles (LNPs) is related to their circulation in the bloodstream. However, incorporating PEGylated lipids in LNPs can extend their circulation time due to their steric barrier effect. It is crucial to carefully control the amount of PEGylated lipids to avoid potential drawbacks. Higher PEG contents in LNPs may lead to longer residence times in the bloodstream but may also hinder the intracellular delivery of nucleic acids.

Additionally, the size of PEG-lipids attached to LNPs can be adjusted to control their rate of diffusion away from the nanoparticles and affect their residence time in circulation. While extending the circulation time of LNPs is desirable for effective drug delivery, it is important to avoid prolonged exposure to PEGylated lipids, as it can promote immunogenicity and the development of anti-PEG antibodies. These antibodies may lead to accelerated clearance of the LNPs, acute hypersensitivity reactions and reduced drug efficacy. To overcome this issue, modifications to the PEG molecules to reduce their immunogenicity or exploring alternative administration routes may offer potential solutions.

Specificity

One of the critical aspects being explored is the specificity of LNPs in drug delivery. Despite their numerous advantages, LNPs lack inherent targeting capabilities. Upon systemic administration, LNPs can disperse widely throughout the body, leading to interactions with diseased and healthy tissues. This lack of specificity may result in off-target effects and potential adverse reactions. To address this limitation, researchers are exploring surface modification by targeting ligands to enhance precision in drug delivery and minimize unintended interactions with healthy cells.

Future Perspectives of Lipid Nanoparticles

Lipid nanoparticles hold great potential for future advancements in healthcare, including personalized medicine, cancer immunotherapy and infectious disease vaccines. Emerging targeted lipid nanoparticles offer a promising approach for CRISPR-Cas9 gene editing in cancer, facilitating precise delivery of the gene-editing machinery to tumor cells for potential therapeutic interventions. Solid tumors remain a key target for therapeutic intervention due to their difficulty in accessing and their resistance to treatment. These make them attractive for targeting with LNPs.

recent-articles